142 results match your criteria: "Rhinitis Medicamentosa"

Adherence to positive airway pressure (PAP) therapy is a challenge in patients with allergic rhinitis. We present a case of a 62-year-old male with OSA who had been struggling with PAP therapy for ten years. Intranasal fluticasone alone did not result in tolerance of PAP therapy.

View Article and Find Full Text PDF

Outcomes after Functional Nasal Surgery in Patients with Versus without Rhinitis Medicamentosa.

Laryngoscope

October 2024

Department of Otolaryngology-Head and Neck Surgery, Henry Ford Health, Detroit, Michigan, U.S.A.

Objective: Topical nasal decongestants (TNDs) are used to reduce nasal soft tissue edema and obstruction. However, after frequent TND use, patients can develop rhinitis medicamentosa (RM) with rebound nasal edema and obstruction. Management of RM has centered largely on TND cessation ± intranasal corticosteroids.

View Article and Find Full Text PDF

Rise and fall of decongestants in treating nasal congestion related diseases.

Expert Opin Pharmacother

October 2024

Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.

Article Synopsis
  • Decongestants are medicines that help relieve stuffy noses caused by illnesses like colds and allergies.
  • This article reviews research to help doctors use decongestants safely and effectively for their patients.
  • It's important to use decongestants carefully and avoid buying products with unknown ingredients, as improper use can cause more problems.
View Article and Find Full Text PDF
Article Synopsis
  • - Sales of over-the-counter decongestant nasal sprays in Denmark have doubled from 2011 to 2023.
  • - Prolonged use of these sprays can lead to risks like rhinitis medicamentosa, a condition that worsens nasal congestion.
  • - There is a crucial need for better patient education on safe usage and side effects, along with more research to help health authorities regulate these products effectively.
View Article and Find Full Text PDF

Background: Rhinitis medicamentosa is a nonallergic inflammation of the nasal mucosa caused by topical decongestants overuse. It mainly affects young and middle-aged adults. Therefore, the aim of this study was to investigate the attitudes of pharmacists regarding the utilization of over-the-counter intranasal decongestants.

View Article and Find Full Text PDF

Rhinitis medicamentosa - comparing two treatment strategies: a retrospective analysis.

J Laryngol Otol

February 2024

Department of Otolaryngology - Head and Neck Surgery, Lady Davis Carmel Medical Center and Ruth and Bruce Rappaport Faculty of Medicine, and Technion - Israel Institute of Technology, Haifa, Israel.

Objective: Rhinitis medicamentosa poses a therapeutic challenge for both patients and physicians. Treatment strategies vary, starting with avoidance of decongestants, followed by medications or surgical intervention. This study aimed to compare two treatment strategies for this condition.

View Article and Find Full Text PDF

Chronic nasal dysfunction: A clinical case illustrating the concept in practice.

Eur Ann Otorhinolaryngol Head Neck Dis

November 2023

Université Clermont Auvergne, CHU Clermont-Ferrand, INRAE, UNH, équipe ASMS, 63000 Clermont-Ferrand, France; CHU de Clermont-Ferrand, service d'oto-rhino-laryngologie et chirurgie cervico-faciale, 63003 Clermont-Ferrand, France.

Introduction: We illustrate the diagnostic method for chronic nasal dysfunction by an observation in which the clinical history was compared to preoperative responses on the DyNaChron self-administered questionnaire, with ENT interpretation of the sinonasal CT scan preceding and guiding nasal endoscopy.

Case Report: The initial suspicion of rhinitis medicamentosa was transformed by the radiological and endoscopic findings of chronic respiratory rhinitis signs. Prick tests showing sensitivity to dust mites then suggested an allergic origin of the mucosal inflammation, which affected neither the olfactory nose nor the paranasal sinuses.

View Article and Find Full Text PDF

Long-term treatment outcomes in refractory rhinitis medicamentosa managed with nasal surgery.

Int Forum Allergy Rhinol

March 2024

Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, University of New South Wales, Sydney, Australia.

Background: Limited treatment options exist for refractory Rhinitis Medicamentosa (RM). The role of surgery after failed medical management is not well defined. Mucosal contact points and restricted airflow often perpetuate decongestant use.

View Article and Find Full Text PDF

Objective: Radiofrequency ablation (RFA) reliefs nasal obstruction and improves quality of life (QoL) in patients suffering from inferior turbinate hypertrophy (ITH). A substantial benefit was noted among patients suffering from Rhinitis Medicamentosa (RM), enabling ending decongestant spray abuse. Our aim was to establish the benefit from RFA with respect to QoL in patients suffering from ITH, due to the presence of RM.

View Article and Find Full Text PDF

The Indispensable Nasal Decongestant: Patients' Views and Perspectives on Nasal Decongestant Overuse.

J Allergy Clin Immunol Pract

February 2023

Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.

Background: Rhinitis medicamentosa (RM) is a type of nonallergic rhinitis caused by prolonged use of nasal decongestants (NDs). Although it is a preventable phenotype of rhinitis, little is known about patients dealing with this condition.

Objective: To gain a better understanding of patients' views and experiences of ND overuse, and potential facilitators and barriers to discontinue the overuse.

View Article and Find Full Text PDF

Objectives: Nasal obstruction (NO) is a very common complaint in the practice of otolaryngology. The cause of NO can be due to inferior turbinate hypertrophy (ITH), which may be a result of allergic rhinitis, hyperreactivity, hormonal causes, rhinitis medicamentosa or idiopathic. The most commonly used treatments today include local nasal or systemic corticosteroids, cauterization or microdebrider, or thermal ablation with radiofrequency, coblation or ablative laser (mainly carbon dioxide or diode lasers), and submucosal reduction.

View Article and Find Full Text PDF

Objective: To compare the efficacy and safety of a fixed dose combination of Fluticasone Furoate and Oxymetazoline Hydrochloride Nasal Spray 27.5/50 mcg (FDC) with Fluticasone Furoate Nasal Spray 27.5 mcg (Fluticasone) in the management of allergic rhinitis.

View Article and Find Full Text PDF

Background: Non-allergic rhinitis (NAR) can be subdivided into several phenotypes: rhinorrhea of the elderly, rhinitis medicamentosa, smokers', occupational, hormonal, drug-induced, gustatory, and idiopathic rhinitis. There are two pathophysiological endotypes of NAR: inflammatory and neurogenic. Phenotypes may serve as an indicator of an underlying endotype and, therefore, help to guide the treatment.

View Article and Find Full Text PDF

Objective: Our aim in this study is to reveal the expression of Vascular Endothelial Growth Factor (VEGF) and Inducible Nitric Oxide Synthase (iNOS) in the pathogenesis of rhinitis medicamentosa (RM), which occurs as a result of the overdose and long-term use of topical nasal decongestants.

Methods: In this study, 24 Wistar albino rats were divided into two groups as experimental and control groups. In the experimental group, 50 µl of 0.

View Article and Find Full Text PDF

Rhinitis medicamentosa.

BMJ Case Rep

November 2021

Department of Otolaryngology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

View Article and Find Full Text PDF
Article Synopsis
  • - This study looked at how effective using a combination of intranasal corticosteroid spray and oxymetazoline hydrochloride nasal spray is for treating chronic rhinitis compared to using either spray alone.
  • - Researchers analyzed 130 studies published between September 2016 and June 2020, and found that 4 trials with 838 patients met their criteria, showing significant improvement in nasal congestion when both sprays were used together.
  • - The results indicate that this combination treatment is more effective at reducing rhinitis symptoms and increases nasal volume without causing rhinitis medicamentosa, a condition caused by overuse of nasal sprays.
View Article and Find Full Text PDF

Nasal Cytology in Radiofrequency Turbinate Volume Reduction.

ORL J Otorhinolaryngol Relat Spec

August 2021

Otorhinolaryngology Division, Department of Surgery, University of Eastern Piedmont "A. Avogadro", Novara, Italy.

Introduction: Radiofrequency turbinate volume reduction (RFTVR) is an effective treatment of inferior turbinate hypertrophy. RFTVR can reduce epithelial cell alterations in nasal mucosa. The aim of this observational study was to evaluate the effects of RFTVR on nasal obstruction and cytology, stratifying for different types of rhinitis.

View Article and Find Full Text PDF

Recurrent thunderclap headaches from reversible cerebral vasoconstriction syndrome associated with duloxetine, xylometazoline and rhinitis medicamentosa.

CMAJ

November 2020

Division of Allergy and Immunology (Pham), Department of Medicine, McGill University Health Centre, Montréal, Que.; Division of Neurology (Gosselin-Lefebvre), Centre hospitalier universitaire de Québec-Hôpital de l'Enfant-Jésus, Université Laval, Québec, Que.; Division of Allergy and Immunology (Pourshahnazari), University of British Columbia; Division of Neurology (Yip), Vancouver General Hospital, University of British Columbia, Vancouver, BC.

View Article and Find Full Text PDF
Article Synopsis
  • - Rhinitis medicamentosa, or rebound congestion, happens when overly using nasal decongestants like oxymetazoline causes inflammation and worsens nasal obstruction.
  • - A study on Wistar-albino rats found that oxymetazoline decreased certain proteins linked to cell survival and increased markers of cell death, indicating potential damage caused by the drug.
  • - Erdosteine, an antioxidant agent, showed a significant increase in a protective protein, suggesting it may help counteract some of the harmful effects of oxymetazoline by supporting cell health.
View Article and Find Full Text PDF

One type of non-allergic non-infectious rhinitis is represented by a heterogeneous group of rhinitis medicamentosa, which can be divided into several pathogenetic types. The most common rebound nasal congestion associated with the use of topical decongestants. Excessive use of intranasal decongestants leads to a decrease in the number of alpha-adrenoreceptors on the surface of cell membranes and uncoupling their connection with the G-protein and the development of tachyphylaxis.

View Article and Find Full Text PDF

Predisposing factors of rhinitis medicamentosa: what can influence drug discontinuation?

Rhinology

June 2020

"A. Gemelli" Hospital Foundation, IRCCS, Head and Neck Surgery Area, Institute of Otorhinolaryngology, Catholic University of the Sacred Heart. Rome, Italy.

Background: the primary end point of our study was to define risk factors and identify the underlying conditions that may have led to the abuse of vasoconstrictors in rhinitis medicamentosa. Moreover, we analysed factors that may influence the vasoconstrictors discontinuation.

Methodology: this was a prospective case-control observational study.

View Article and Find Full Text PDF

Rhinitis medicamentosa: a nationwide survey of Canadian otolaryngologists.

J Otolaryngol Head Neck Surg

December 2019

Department of Surgery, Division of Otolaryngology - Head and Neck Surgery, Dalhousie University, Halifax, Nova Scotia, Canada.

Background: Rhinitis medicamentosa is a non-allergic form of rhinitis that is typically caused by prolonged use of topical nasal decongestants. This condition commonly affects young adults and treatment is not trivial. We aimed to survey Canadian Otolaryngologists to determine practice patterns and their opinions regarding this under-studied condition.

View Article and Find Full Text PDF

Intranasal corticosteroids for non-allergic rhinitis.

Cochrane Database Syst Rev

November 2019

Academic Medical Centre, Department of Otorhinolaryngology, Meibergdreef 9, A2-234, 1105 Az, Amsterdam, Netherlands.

Article Synopsis
  • Non-allergic rhinitis is a common condition affecting 10-20% of people, characterized by symptoms like nasal obstruction and sneezing due to various non-allergenic triggers.
  • There is currently a lack of effective treatments due to insufficient understanding of its underlying mechanisms, with intranasal corticosteroids being commonly prescribed, though their true efficacy remains unclear.
  • The study aims to evaluate the effectiveness of intranasal corticosteroids through randomized controlled trials, comparing them to placebo or other treatments in individuals aged 12 and older.
View Article and Find Full Text PDF